Main menu
Planet 1 trial rosuvastatin

Planet 1 trial rosuvastatin

Feb 3, 2015 I was a randomised, double-blind, parallel-group done in 147 research centres in Argentina, Brazil, Bulgaria, Canada, Denmark, France, Hungary, Italy, Mexico, Romania, and the USA. We enrolled patients with type or type 2 diabetes aged 18 years or older with proteinuria :181-90. doi: 10.1016/S2213-858770246-3. Epub 2015 Feb 4. Renal effects of atorvastatin and in patients with diabetes who have progressive renal disease : a randomised clinical . de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Jul 5, 2010 The two randomized double-blind multinational tested the effects of atorvastatin 80 mg/day or 10 or 40 mg/day on urinary protein excretion and renal function in I involved 325 patients with type or 2 diabetes, and II involved 220 patients without diabetes. Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease The purpose of this is to evaluate the effects of Crestor and atorvastatin on urinary protein excretion over year in non-diabetes with moderate proteinuria and Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease The purpose of this is to evaluate the effects of Crestor and atorvastatin on urinary protein excretion over year in patients with Type or 2 diabetes with moderate Nov 28, 2017 Full-Text Paper : Effects of and Atorvastatin on Renal Function - Meta-Analysis. Several clinical have reported inconsistent findings for the effects of and atorvastatin on renal function. The aim of In viagra for men the and 2 trials, diabetic and non-. Jan 12, 2017 Chronic kidney disease has been emerged as an important rosuvastatin health concern and is a major cause of premature mortality and comorbidities []. .. Renal effects of atorvastatin and in patients with diabetes who have progressive renal disease : a randomised clinical . However, to date, most large prospective, clinical specifically in patients with various stages of CKD have failed to show a benefit for statins in reducing .. I47, Atorvastatin 80 mg. 10 mg. 40 mg - year follow-up, n=325 eGFR:68.8–72.6 mL/min/1.73 m2. LDL-C: 150–156 mg/dL Mar 30, 2009 els was 43% in patients receiving , from a mean baseline level of 100 mg .. A per-pro- tocol analysis of patients who continued to receive active medication until they reached a . Table . Characteristic .. and AURORA advisory committees for AstraZeneca;. Jul 19, 2010 The goal of the was to evaluate treatment with atorvastatin compared with among diabetic patients and nondiabetic patients with hypercholesterolemia and moderate proteinuria. Type 2 diabetes was present in 86% and type diabetes in 14%. Change in Mar 3, 2015 The I showed reduced urinary protein excretion, but unaffected eGFR in patients with diabetes and proteinuria who were treated during year with atorvastatin 80 mg. In patients randomised to 40 mg, urinary protein excretion was not changed, but eGFR decreased as compared IDEAL: Design. * Simvastatin dose was increased to 40 mg/day at week 24 in patients whose plasma total cholesterol remained 5.0 mmol/L or .. and 2: Primary Endpoint - Effect on Proteinuria. 10 mg. 40 mg. Atorvastatin 80 mg. . Urinary protein excretion. Jul 18, 2010 The two randomized double-blind multinational tested the effects of atorvastatin. 80 mg/day or 10 or 40 mg/day on urinary protein excretion and renal function in hypercholesterolemic patients with moderate proteinuria. I involved 325 patients with type or trials 2 diabetes, Oct 13, 2011 Mehra and Desai, J Nephrol Therapeutic 2011, : Numerous have shown that chronic kidney disease increases the risk of cardiovascular disease. . . I and II both aimed to compare effects of and atorvastatin on reducing urinary protein. Mar 24, 2015 on proteinuria and other renal end points.3 . The were initially presented in 2010 and have now been published in The. Lancet Diabetes and Endocrinology.3 The. I cohort included patients with type or type 2 dia betes. Jul 23, 2011 I involved 353 patients with type or 2 diabetes with a mean eGFR of 71.2 ml/min/1.73 m 2, and . II involved 237 patients with PLANET a mean eGFR of 74.9 ml/ min/1.73 m 2 at baseline [30] . For I, atorvastatin significantly reduced proteinuria by about 15%, whereas had no Jan 23, 2011 The and 2 studies are not widely publicized. renal function, there was a significant decline in renal function and failure to reduce urinary protein in patients randomized to but not atorvastatin. Nevertheless, the design of the appears sound and the number of patients adequate. Mar 17, 2015 Renal effects of atorvastatin and in patients with diabetes who have progressive renal disease : a randomised clinical . Lancet Diabetes Endocrinol 2015 Feb 4 [Epub ahead of print.] The statin wars: why AstraZeneca must retreat. Lancet 2003;362:1341. McKillop T. Letter to the Feb 21, 2016 hydroxymethylglutaryl-CoA reductase inhibitor; lipid lowering; dyslipidemia; atorvastatin; ; simvastatin . . Rate of change in eGFR per year. We pooled eGFR data calculated by the MDRD formula, CKD-EPI or I, Randomized double blind, multicenter , 325 patients with diabetes who had proteinuria and hypercholesterolemia, year, 10 mg/day or 40 trials mg/day versus atorvastatin 80 mg/day, Change in urinary protein excretion , Atorvastatin significantly reduced
Website URL:

FacebookG+TwitterRSS